Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
The biopharma industry showed signs of recovery in the third quarter (Q3) of 2024, with increased investor optimism following the interest rate cuts by the US Federal Reserve in September 2024, according to GlobalData. 29 October 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
As the World Health Organization (WHO) calls for advancements to combat serious infections, one American firm is raising awareness about its work on nanoparticles. 17 July 2024
Biotechnology
Cardurion Pharmaceuticals, which is developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced a $260 million Series B financing. 16 July 2024
Biotechnology
Nucleome Therapeutics, a UK biotech using spatial genomics to discover precision medicines for complex diseases, has appointed Mark Bodmer as chief executive. 16 July 2024
Biotechnology
Switzerland-based Asceneuron, a biotech developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, has announced a $100 million oversubscribed Series C financing. 16 July 2024
Biotechnology
Côte d’Ivoire has become the first country to begin administering the new R21/Matrix-M vaccine. 16 July 2024
Pharmaceutical
The USA's BARDA has announced up to $500 million in Project NextGen funding to plan and execute multiple Phase IIb clinical trials evaluating novel vaccines administered as a nasal spray or as a pill to protect against symptomatic COVID-19. 16 July 2024
Biotechnology
Cambridge, USA-based biotech Rectify Pharmaceuticals today announced the appointment of Bharat Reddy as chief business officer (CBO). 15 July 2024
Generics
India-based generic drugmaker Lupin Limited says it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for topiramate extended-release capsules. 15 July 2024
Biotechnology
M&A news last week featured US pharma major Eli Lilly announcing a $3.2 billion bid to acquire gastroenterology specialist Morphic. On the research front, US clinical-stage biotech HilleVax announced disappointing Phase IIb results with its norovirus vaccine HIL-214. Also, Dutch firm uniQure pleased investors with early--stage results for its investigational Huntington’s disease drug AMT-130, and US pharma gian
t Pfizer announced it is progressing its Parkinson’s disease candidate danuglipron. 14 July 2024
Latest In Brief for Alnylam Pharmaceuticals
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Relevant Ones To Watch News
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
8 November 2024
24 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze